NCT06510283View on ClinicalTrials.gov

Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Interventions
DRUG

Taitacept

Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.

Trial Locations (1)

100730

RECRUITING

Beijing Tongren Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER

NCT06510283 - Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis | Biotech Hunter | Biotech Hunter